ENGN enGene Therapeutics Inc. Common Stock
XNAS
4.10
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
ENGN
$4.10
—
Key stats
$4.10
- 52-Week Range
- $1.40 – $12.25
- YTD
- -53.67%
- Straddle Price
- $4.65
- P/C Vol Ratio
- 1.00
- Market Cap
- $0.1B
- Open
- $1.68
- Day Range
- $1.59 – $1.68
- Volume
- 1,108,892
- Prev Close
- $1.67
Fair Value
+50.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.15% |
| Beta vs SPY | 0.56 |
| Cost of Equity (CAPM) | 7.94% (VRP-adj) |
| WACC | 7.45% |
| Volatility Risk Premium | +340.1pp (IV − HV30) |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.1B |
| Return on Equity (TTM) | -56.6% |
| Book / Price | 219.0% — banking bias active (P/B is primary) |
| Debt / Equity | 0.11 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $1.82 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $1.79 |
| Bollinger Width / SMA20 | 1788.4% (drives anchor stability) |
| Net Debt | $-0.0B |
| Market Cap | $0B |
Peers used for multiples: AMGN, BIIB, EXEL, GILD, HALO, MRNA, NBIX, RGEN, RVMD, TECH
(SIC-code peers; ETF co-membership was sector-incoherent)
Blended Fair Value
$10.78
Deviation
+50.0%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 34.1× · 7 peers |
| Peer EV/EBITDA | n/a | 0% | median 18.0× · 8 peers |
| Peer P/B | $40.94 | 23% | median 11.5× · 10 peers |
| Peer P/S | n/a | 0% | median 6.5× · 9 peers |
| Market Anchor (SMA50) | $1.82 | 77% | stability 66% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-10-22 · updated
Related
About
- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
- Exchange
- XNAS
- Market Cap
- $0.1B
- Employees
- 82
- List Date
- 2023-11-01
- CIK
- 0001980845
- Headquarters
- Saint-Laurent
- Homepage
- https://www.engene.com
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresp…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|
| Jan | -- | -14.41% | -5.10% | 7.68% | -3.94% |
| Feb | -- | 74.76% | -10.16% | 1.10% | 21.90% |
| Mar | -- | 9.57% | -23.29% | -31.90% | -15.21% |
| Apr | -- | -5.86% | -4.39% | 7.54% | -0.90% |
| May | -- | -44.68% | 2.67% | -74.48% | -38.83% |
| Jun | -- | 17.87% | -8.54% | -2.81% | 2.17% |
| Jul | -- | 4.97% | 4.70% | 1.42% | 3.70% |
| Aug | -- | -20.77% | 20.63% | 3.95% | 1.27% |
| Sep | -- | -1.79% | 42.29% | 7.82% | 16.11% |
| Oct | -- | 35.94% | -5.13% | -17.68%* | 4.38% |
| Nov | -61.70% | -2.70% | 16.62% | -- | -15.93% |
| Dec | 23.07% | -23.12% | 14.16% | -- | 4.70% |
| Total | -52.86% | -16.44% | 33.28% | -81.50% | -29.38% |
* Only 4 year(s) of data available.
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $1.79
SMA 50: $1.82
SMA 200: $4.61
Current: $1.63
EMA 12: $1.70
EMA 26: $1.77
MACD: -0.0703 | Signal: -0.0185
BEARISH
ADX (14): 24.55
WEAK TREND
+DI: 17.06
−DI: 26.26
Momentum Oscillators
RSI (14): 40.67
NEUTRAL
Stoch %K: 14.49
Stoch %D: 17.39
Williams %R: -84.78
Volume & Volatility
BB Upper: $2.08
BB Lower: $1.50
NEUTRAL
OBV: 10,452,673
Vol SMA 20: 894,545
Vol ROC: 56.56%
ATR: $0.10
True Range: $0.09
HV 20: 58.7%
HV 30: 54.9%
HV 60: 51.5%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-23T00:00:00 – 2026-10-21T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary
BULLISH (8/10)
Key drivers: Strong momentum signals, support from technical indicators, and relatively low volatility.
Primary risks: High beta and potential for increased volatility if market conditions change.
Investment thesis: ENGN has a strong short-term trend, supported by medium-term technical indicators. The stock's high beta could lead to significant moves in either direction, making it suitable for traders seeking momentum plays.
Recent news sentiment impact: Neutral news headlines have not significantly impacted the stock's price movement, which is driven more by technical signals.
Technical Analysis
Trend Direction: Short-term (1-4 weeks): Bullish; Medium-term (1-3 months): Neutral; Long-term (3-12 months): Bearish
Support/Resistance Levels: Key levels to monitor: $1.77 (SMA 20), $1.86 (upper Bollinger Band), and $1.68 (lower Bollinger Band)
Momentum Signals:
- RSI interpretation: Neutral (47.28)
- MACD signal: Bearish (MACD -0.04, Signal 0.01, Histogram -0.05)
- Bollinger Bands position: Neutral (price near middle band)
News & Sentiment Analysis
Recent Headlines Summary: Neutral news headlines have not significantly impacted the stock's price movement.
Sentiment Assessment: Aggregate news sentiment: NEUTRAL
Catalyst Identification: No significant upcoming events or announcements that could impact the stock's price movement.
Market Narrative: Technical signals are driving the stock's price movement, while recent news headlines have had a neutral impact.
Risk & Volatility Assessment
Beta Interpretation: High beta (2.26) indicates high volatility and increased risk relative to market.
Volatility Regime: Current vs historical volatility levels: Higher than average (1.23)
Options Market Signals:
- IV Rank: 100.0% (High)
- Put/Call Volume Ratio: Bearish sentiment (9.32)
Market Context & Positioning
Sector Performance: Relative strength vs sector/market: Neutral
Institutional Activity: No significant institutional activity signals or volume patterns suggesting institutional interest.
Correlation Analysis: How stock moves relative to market (R-squared interpretation): High correlation (0.24)
Relative Valuation: Position within trading range: Neutral
Key Levels & Action Items
Critical Price Levels: Support/resistance levels to monitor: + $1.77 (SMA 20) + $1.86 (upper Bollinger Band) + $1.68 (lower Bollinger Band)
Breakout/Breakdown Levels: Technical levels that could trigger significant moves: SMA 50, SMA 200
Time-Sensitive Catalysts: No immediate earnings dates or product launches to drive price movement.
Risk Management: Stop-loss levels and position sizing considerations: + Set stop-loss at $1.68 (lower Bollinger Band) for long positions + Consider reducing position size due to high beta
Generated
News
All ENGN news →
Earnings History
1 of 1 under expected move
Avg Expected Move
18.23%
Avg Actual Move
3.65%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2026-09-08 | unknown | 18.23% | 3.65% | 0.20x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
ENGN Options Activity & IV Rank
Volatility Metrics
Current IV: —
7-DTE IV: —
Expected Move: $4.65
7-DTE Move: $4.65
Days to Exp: 30 (2026-11-20)
Options Flow
Call Volume: 211
Put Volume: 210
P/C Volume: 0.995
NEUTRAL
Call OI: 730
Put OI: 210
P/C OI: 0.288
Total OI: 940
ATM Options Pricing
ATM Call: $2.50
ATM Put: $2.15
Call %: 61.0%
Put %: 52.4%
Chain Summary
Chain Volume: 799
Chain OI: 13,221
Last Updated: 10/21/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
LOW γ vs HISTORY
Estimated net dealer gamma is at the 7th percentile of this name's own daily history, near the low end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
7%
vs own history
GEX tilt
+0.37
OI-weighted, today
Vanna tilt
+0.47
δ-sensitivity to IV
Charm tilt
-0.21
δ-decay vs time
Vanna tilt +0.47: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
? What is this?
· 3 ATM contracts, 1k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 21 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Oct 21 · No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)$4.65Oct 21
Beta Analysis
Risk Metrics
Beta: 2.0735
Alpha: -79.08%
Correlation: 0.2233
R-Squared: 5.0%
Stock Volatility: 117.9%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own ENGN
4 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Millennium Management Hedge fund Izzy Englander | $1.7M | #2667 of 3716 | new | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $1.4M | #2146 of 3138 | new | 13F | |
| Citadel Hedge fund Ken Griffin | $1.2M | #3449 of 6285 | new | 13F | |
| Point72 Hedge fund Steve Cohen | $24K | #1911 of 1945 | new | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
ENGN Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 64,526,622 (as of 2026-07-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
3 filers$193.24K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $107.09K | 55.42% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $53.28K | 27.57% | 2026-06-30 |
| 3 | Jane Street Group, LLC Custodian | $32.87K | 17.01% | 2026-06-30 |
3 filers$693.21K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $541.66K | 78.14% | 2026-06-30 |
| 2 | Jane Street Group, LLC Custodian | $94.80K | 13.68% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $56.74K | 8.19% | 2026-06-30 |
ENGN Insider Trading (Form 4)
Latest: 2026-09-24Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-09-24 | William Grossman | Interim Chief Medical Officer | Buy (P) | +5,102 | $1.97 | $10.1K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
ENGN Insider Holdings
1 insider · @ $1.63
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | William Grossman | Interim Chief Medical Officer | 5,102 | $8.3K | $10.1K | 1 | 2026-09-24 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ENGN Board & Officers
As of SEC filings through Sep 24, 2026Directors 9
- Gerald A Brunk · since Oct 31, 2023
- Richard M Glickman · since Oct 31, 2023
- Lota S. Zoth · since Dec 18, 2023
- Paul J Hastings · since May 15, 2024
- Wouter Joustra · since May 15, 2024
- Ronald Harold Wilfred Cooper · since Jul 22, 2024
- Michael Thomas Heffernan · since Jul 8, 2025
- Philip Astley-Sparke · since Jul 8, 2025
- William Grossman · since Jul 8, 2025
Officers 12
- Ronald Harold Wilfred Cooper · CEO & President · listed since Jan 2025
- D. Ryan Daws · Chief Financial Officer · since Nov 27, 2023
- Lee Giguere · Chief Legal Ofc. and Corp Secy · since Jan 29, 2024
- Joan Connolly · Chief Technology Officer · since Oct 21, 2024
- Anthony Tzeyew Cheung · Chief Scientific Officer · listed since Oct 2024
- Alexander Julian Nichols · Chief Strategy & Ops. Ofc · listed since Jan 2025
- Amy Pott · Chief Global Comm. Ofc. · since May 27, 2025
- Jill Buck · Chief Development Officer · since Jul 8, 2025
- Matthew Ross Boyd · Chief Regulatory Officer · since Jul 8, 2025
- William Grossman · Interim Chief Medical Officer · listed since Jun 2026
- Constantine Chinoporos · Interim Chief Business Officer · since Jul 16, 2026
- Kathleen P. Richton · SVP, Finance and Treasurer · since Jul 16, 2026
Changes in the last 10 years (53)
| Jul 16, 2026 | Kathleen P. Richton became SVP, Finance and Treasurer |
| Jul 16, 2026 | Constantine Chinoporos became Interim Chief Business Officer |
| Jun 17, 2026 | William Grossman first listed as Interim Chief Medical Officer in an SEC filing |
| Jun 13, 2026 | The company announced the departure of Hussein Sweiti as Chief Medical Officer in an SEC filing |
| Sep 29, 2025 | Hussein Sweiti became Chief Medical Officer |
| Jul 8, 2025 | William Grossman became a director |
| Jul 8, 2025 | Philip Astley-Sparke became a director |
| Jul 8, 2025 | Michael Thomas Heffernan became a director |
| Jul 8, 2025 | Matthew Ross Boyd became Chief Regulatory Officer |
| Jul 8, 2025 | Jill Buck became Chief Development Officer |
| Jul 7, 2025 | The company announced the departure of Jasper Bos from the board in an SEC filing |
| Jun 3, 2025 | The company announced the departure of Raj Som Pruthi as Chief Medical Officer in an SEC filing |
| May 27, 2025 | Amy Pott became Chief Global Comm. Ofc. |
| Jan 31, 2025 | Ronald Harold Wilfred Cooper listed as CEO & President (previously Chief Executive Officer) in SEC filings |
| Jan 31, 2025 | Alexander Julian Nichols listed as Chief Strategy & Ops. Ofc (previously Pres. & Chief Operating Ofc.) in SEC filings |
| Oct 22, 2024 | Anthony Tzeyew Cheung listed as Chief Scientific Officer (previously Chief Technology Officer) in SEC filings |
| Oct 21, 2024 | Joan Connolly became Chief Technology Officer |
| Oct 16, 2024 | The company announced the departure of James Crowley Sullivan as Chief Scientific Officer in an SEC filing |
| Jul 22, 2024 | The company announced the departure of Jason David Hanson from the board in an SEC filing |
| Jul 22, 2024 | Ronald Harold Wilfred Cooper became a director |
| Jul 22, 2024 | Ronald Harold Wilfred Cooper became Chief Executive Officer |
| Jul 22, 2024 | Raj Som Pruthi became Chief Medical Officer |
| Jun 18, 2024 | Gerald A Brunk no longer listed as a 10% owner in SEC filings |
| May 15, 2024 | Wouter Joustra became a director |
| May 15, 2024 | Paul J Hastings became a director |
| Apr 22, 2024 | De Solidarite Des Travailleurs Du Quebec Fonds reported in an SEC filing no longer being a 10% owner |
| Feb 21, 2024 | Lumira Capital Investment Management Inc. reported in an SEC filing no longer being a 10% owner |
| Feb 13, 2024 | The company announced the departure of Jason David Hanson as Chief Executive Officer in an SEC filing |
| Jan 29, 2024 | Lee Giguere became Chief Legal Ofc. and Corp Secy |
| Dec 18, 2023 | Lota S. Zoth became a director |
| Nov 27, 2023 | D. Ryan Daws became Chief Financial Officer |
| Nov 2, 2023 | Gerald A Brunk first listed as a 10% owner in an SEC filing |
| Oct 31, 2023 | Richard Paul Bryce became Chief Medical Officer |
| Oct 31, 2023 | Richard M Glickman became a director |
| Oct 31, 2023 | Mark N Lampert became a 10% owner |
| Oct 31, 2023 | Lumira Capital Investment Management Inc. became a 10% owner |
| Oct 31, 2023 | Jasper Bos became a director |
| Oct 31, 2023 | Jason David Hanson became a director |
| Oct 31, 2023 | Jason David Hanson became Chief Executive Officer |
| Oct 31, 2023 | James Crowley Sullivan became Chief Scientific Officer |
| Oct 31, 2023 | Gerald A Brunk became a director |
| Oct 31, 2023 | Forbion III Management B.V. became a 10% owner |
| Oct 31, 2023 | Forbion Capital Fund III Cooperatief U.A. became a 10% owner |
| Oct 31, 2023 | De Solidarite Des Travailleurs Du Quebec Fonds became a 10% owner |
| Oct 31, 2023 | Bvf Partners L P/il became a 10% owner |
| Oct 31, 2023 | Bvf Inc/il became a 10% owner |
| Oct 31, 2023 | Bvf Gp Holdings LLC became a 10% owner |
| Oct 31, 2023 | Anthony Tzeyew Cheung became Chief Technology Officer |
| Oct 31, 2023 | Alexandre Jean-Rene Erwan Grassin became Int. Chief Financial Officer |
| Oct 31, 2023 | Alexander Julian Nichols became Pres. & Chief Operating Ofc. |
| Oct 30, 2023 | Forbion Growth Sponsor FEAC I B.V. became a 10% owner |
| Oct 30, 2023 | Forbion Growth Opportunities Fund I Cooperatief U.A. became a 10% owner |
| Oct 30, 2023 | Forbion Growth Management B.V. became a 10% owner |
Not reported recently (11)
- Forbion Growth Management B.V. · Last reported as a 10% owner in an SEC filing dated Nov 1, 2024
- Forbion Growth Opportunities Fund I Cooperatief U.A. · Last reported as a 10% owner in an SEC filing dated Nov 1, 2024
- Richard Paul Bryce · Last reported as Chief Medical Officer in an SEC filing dated Dec 4, 2023
- Bvf Partners L P/il · Last reported as a 10% owner in an SEC filing dated Nov 13, 2023
- Bvf Inc/il · Last reported as a 10% owner in an SEC filing dated Nov 13, 2023
- Mark N Lampert · Last reported as a 10% owner in an SEC filing dated Nov 13, 2023
- Bvf Gp Holdings LLC · Last reported as a 10% owner in an SEC filing dated Nov 13, 2023
- Forbion III Management B.V. · Last reported as a 10% owner in an SEC filing dated Nov 13, 2023
- Forbion Capital Fund III Cooperatief U.A. · Last reported as a 10% owner in an SEC filing dated Nov 13, 2023
- Forbion Growth Sponsor FEAC I B.V. · Last reported as a 10% owner in an SEC filing dated Nov 2, 2023
- Alexandre Jean-Rene Erwan Grassin · Last reported as Int. Chief Financial Officer in an SEC filing dated Oct 31, 2023
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ETF Holders
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-2.08
TTM Revenue
$0.00
TTM Net Income
$-130.36M
TTM Op. Cash Flow
$-103.31M
Quarterly figures (2 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q3 '26 | 2026-07-31 | $0.00 | $-32.50M | $-0.47 | $-18.95M |
| Q3 '25 | 2025-07-31 | $0.00 | $-28.99M | $-0.57 | $-25.63M |
Q3 2026 • period ending 2026-07-31 • filed 2026-09-08
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
0.46
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-56.6%
ROA
-45.2%
Div Yield
0.00%
FCF Yield
-98.22%
Debt/Equity
0.11
Current Ratio
—
Market Cap
$105.18M
as of 2026-10-21
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
1.39M
SI % of Float
3.16%
Days to Cover
1.81
Short Vol Ratio
39.7%
Free Float
44.07M
Float %
65.8%
Short interest 2026-09-30 • Short volume 2026-10-21 • Float 2026-08-14